Are GLP-1 receptor agonists (GLP-1 RAs) destined to become lifelong medications? This question has sparked intense debate, especially after a recent systematic review published in the BMJ (https://www.bmj.com/content/392/bmj-2025-085304) shed light on what happens when patients stop these treatments. But here’s where it gets controversial: while these drugs are effective for weight loss and managing cardiometabolic risks, the review found that weight and health markers often rebound rapidly once treatment stops—sometimes faster than with other interventions. This raises a critical question: should patients even start these medications in the first place? Let’s dive into the evidence and expert insights to unpack this complex issue.
The Rebound Effect: More Than Just Weight Gain
The BMJ analysis revealed that weight regain is almost inevitable after discontinuing GLP-1 RAs. But it’s not just about the numbers on the scale. Cardiometabolic risk markers—like blood pressure, glucose, and lipid levels—also revert to pre-treatment levels. And this is the part most people miss: the rebound isn’t a sign of treatment failure but rather a reflection of how these drugs work. GLP-1 RAs amplify existing hormonal signals in the body, particularly those regulating appetite, digestion, and satiety. Once the medication stops, these effects fade, leading to rapid changes.
Professor Clare Collins, a nutrition and dietetics expert from the University of Newcastle, emphasizes that this pattern is entirely predictable. ‘If someone stops taking antihypertensives, their blood pressure rises,’ she explains. ‘The real issue isn’t the predictability of the rebound—it’s the need for better long-term maintenance strategies.’ While weight regain grabs headlines, Prof Collins highlights the more alarming deterioration in metabolic markers, which underscores the importance of sustained care.
The Role of Nutrition: The Missing Piece of the Puzzle
Here’s a bold statement: nutrition is often overlooked in incretin therapy trials. Prof Collins led a systematic review (https://pubmed.ncbi.nlm.nih.gov/41491340/) that found only two out of numerous phase three trials measured and reported dietary intake. Most studies provided generic advice but failed to track how appetite suppression, nausea, or early satiety influenced eating habits over time. This gap leaves clinicians guessing about the long-term impact on diet quality and nutrient adequacy.
For instance, while patients may reduce calorie intake, they could still face micronutrient deficiencies or loss of lean muscle mass if nutrition isn’t actively monitored. Pharmacists, with their frequent patient interactions, are uniquely positioned to spot these issues early and refer patients to dietitians for medical nutrition therapy. Prof Collins also highlights resources like the University of Newcastle’s healthy eating quiz and obesity management podcast (https://nomoneynotime.com.au/) as valuable tools for patients.
Lifelong Treatment or Temporary Fix? The Debate Continues
Associate Professor Trevor Steward, from the Melbourne School of Psychological Sciences, argues that GLP-1 RAs are increasingly viewed as potentially lifelong treatments, similar to medications for other chronic conditions. Given the risks of long-term obesity, continued therapy may be a safer option for some patients. However, this is where opinions diverge: while some clinicians advocate for long-term use, others question the lack of clear evidence on tapering and maintenance strategies. ‘Clinicians are operating in the dark,’ A/Prof Steward notes.
The emotional toll of repeated weight loss and regain cycles cannot be ignored. A/Prof Steward shares the story of a patient who lost over 50 kilograms three times, only to regain it after stopping treatment. ‘She’d rather stay on these medications for life than endure that cycle again,’ he says. This highlights the need for honest conversations about treatment goals and expectations before starting therapy.
Cost, Commitment, and the Future of GLP-1 RAs
While the BMJ findings shouldn’t deter prescribing, Prof Collins stresses the importance of discussing costs early. These medications are a long-term investment, akin to owning a car or a smartphone. However, potential savings in medical visits and other health-related expenses should also be considered. Additionally, emerging evidence suggests some patients might be able to pause treatment and reinitiate at lower doses, though more research is needed.
As GLP-1 RAs gain popularity—with over half a million Australians currently using them—clinical messaging must evolve. Here’s a thought-provoking question: Should these drugs be reserved for patients committed to long-term use, or is it acceptable for individuals to take them for short-term goals, like fitting into a wedding dress? Let’s open the floor for discussion. What do you think? Share your thoughts in the comments below.
For further reading, explore the AP CPD article on weight loss management (https://www.australianpharmacist.com.au/weight-loss-management-cpd/).
